Recombinant CD79a antibody (AA 1-100)
Quick Overview for Recombinant CD79a antibody (AA 1-100) (ABIN7127229)
Target
See all CD79a (CD79A) AntibodiesAntibody Type
Reactivity
Host
Clonality
Conjugate
Application
- 
    - 
                                            Binding Specificity
- AA 1-100
- 
                                            Specificity
- A disulphide-linked heterodimer, consisting of mb-1 (or CD79a) and B29 (or CD79b) polypeptides, is non-covalently associated with membrane-bound immunoglobulins on B cells. This complex of mb-1 and B29 polypeptides and immunoglobulin constitute the B cell Ag receptor. CD79a first appears at pre B cell stage, early in maturation, and persists until the plasma cell stage where it is found as an intracellular component. CD79a is found in the majority of acute leukemias of precursor B cell type, in B cell lines, B cell lymphomas, and in some myelomas. It is not present in myeloid or T cell lines. Anti-CD79a is generally used to complement anti-CD20 especially for mature B-cell lymphomas after treatment with Rituximab (anti-CD20). This antibody will stain many of the same lymphomas as anti-CD20, but also is more likely to stain B-lymphoblastic lymphoma/leukemia than is anti-CD20. Anti-CD79a also stains more cases of plasma cell myeloma and occasionally some types of endothelial cells as well.
- 
                                            Cross-Reactivity (Details)
- Human.
- 
                                            Purification
- 1.0mg/ml of Ab purified from Bioreactor by Protein A/G.
- 
                                            Immunogen
- Recombinant fragment (around aa1-100) of human CD79a protein (exact sequence is proprietary)
- 
                                            Isotype
- IgG
 
- 
                                            
- 
    
- 
    - 
                                            Application Notes
- 
                        Known_Application: Immunohistochemistry (Formalin-fixed) (1-2 μg/mL for 30 minutes at RT),(Staining of formalin-fixed tissues requires heating tissue sections in 10 mM Tris with 1 mM EDTA, pH 9.0, for 45 min at 95 °C followed by cooling at RT for 20 minutes),Optimal dilution for a specific application should be determined. Positive_Control: Daudi or Ramos cells. Germinal center B-cells in a lymph node or tonsil. 
- 
                                            Restrictions
- For Research Use only
 
- 
                                            
- 
    - 
                                            Concentration
- 1.0 mg/mL
- 
                                            Buffer
- Prepared in 10 mM PBS, WITHOUT BSA and Azide.
- 
                                            Preservative
- Azide free
- 
                                            Storage
- -20 °C,-80 °C
- 
                                            Storage Comment
- Antibody without azide - store at -20 to -80 °C. Antibody is stable for 24 months. Non-hazardous.
- 
                                            Expiry Date
- 24 months
 
- 
                                            
- 
    - CD79a (CD79A) (B-cell antigen receptor complex-associated protein alpha chain (CD79A))
- 
                                            Alternative Name
- CD79A
- 
                                            Background
- 
                        B lymphocyte-specific MB1 protein, B-cell antigen receptor complex-associated protein alpha chain, CD79a molecule immunoglobulin associated alpha, Ig-alpha, IGA, IgM-alpha, Immunoglobulin-associated alpha, Ly54, MB-1 membrane glycoprotein, Membrane-bound immunoglobulin-associated protein, Surface IgM-associated protein,CD79a (B-Cell Marker)
 Cellular localisation: Cell Surface
- 
                                            Molecular Weight
- 44kDa
- 
                                            Gene ID
- 973, 631567
- 
                                            UniProt
- P11912
- 
                                            Pathways
- BCR Signaling
 Target
- 
                    
 
                                     
                                     
                                    